Treatment of extensively drug-resistant (XDR) Acinetobacter baumannii infections is challenging because of both the limited choice of antibiotic and the tendency of such infections to occur in critically ill hosts with limited physiologic reserves (17). Polymyxins demonstrate in vitro activity against A. baumannii, but resistance is also reported (8, 17) . In the absence of feasible alternatives, unconventional antibiotics, such as minocycline, rifampin, and tigecycline, have been used, both singly and in combination (19) . In vitro combination susceptibility testing poses a significant challenge for clinical microbiology laboratories, with a lack of standardization and a variety of in vitro testing methods. This study evaluated the effects of various antibiotic combinations against a panel of XDR-Acinetobacter baumannii and compared in vitro synergy testing results obtained from time-kill, checkerboard, and Etest methods.
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(Some elements of this study were presented at the 20th European Congress of Clinical Microbiology and Infectious Diseases, 2010.)
Clinical isolates of antibiotic-resistant A. baumannii were collected from four hospitals in Singapore over a 2-year period. Species identification was confirmed by a multiplex PCR assay (2) . MICs to ampicillin-sulbactam, ciprofloxacin, gentamicin, imipenem, meropenem, aztreonam, piperacillin-tazobactam, polymyxin B, tigecycline, ceftazidime, amikacin, and cefepime were obtained by broth microdilution (Sensititre, Trek Diagnostics, United Kingdom), while MICs for rifampin were obtained by broth macrodilution (3). Categorical susceptibility was based on Clinical and Laboratory Standards Institute breakpoints (4). XDR A. baumannii isolates were defined as isolates that were resistant to all the tested antimicrobials except for tigecycline, rifampin, and polymyxin B (5, 6), while pandrug-resistant (PDR) A. baumannii was resistant to all tested antimicrobial agents (5, 6) . Clonal relatedness of study isolates was determined by multiplex PCR strain typing (11) , with cluster analysis of banding data performed using the unweighted pair group method with arithmetic mean.
All strains were tested for the presence of in vitro synergy to polymyxin B-rifampin, polymyxin B-tigecycline, and tigecycline-rifampin combinations by three methods. These combinations were selected based on previously published data, which demonstrated a high likelihood of achieving in vitro synergy (10) . Time-kill assays were performed following methods published by the Clinical and Laboratory Standards Institute (13), with colony enumeration performed at 0-and 24-h time points. The lower limit of detection was 400 CFU/ml. Antibiotic concentrations used for the time-kill assay were 2 mg/liter for each antibiotic, representing achievable serum concentrations for polymyxin B (9) and rifampin (7) and achievable tissue levels for tigecycline (18) .
Etest and checkerboard synergy testing were performed according to published methods (12, 20) . Fractional inhibitory concentrations (FIC) were calculated as follows: FIC of drug A ϭ MIC of drug A in combination/MIC of drug A alone; FIC of drug B ϭ MIC of drug B in combination/MIC of drug B alone. The FIC index (FICI) was defined as the FIC of drug A added to the FIC of drug B.
The definition of synergy for time-kill assays used was a Ն2-log 10 decrease in CFU/ml for the antibiotic combination compared with its more active constituent (13) . For Etest and checkerboard assays, the FICI was interpreted as follows: synergy, FICI Յ 0.5; antagonism, FICI Ͼ 4.0; and indifferent, 0.5 Ͻ FICI Ͻ 4.0 (14) .
Thirty-six isolates of A. baumannii were received, of which 4 (11%) isolates were PDR A. baumannii, with the remaining categorized as XDR A. baumannii. Categorical susceptibility was not reported for rifampin (MIC range, 2 to Ն32 mg/liter) and tigecycline (MIC range, 2 to Ն32 mg/liter). Molecular typing data demonstrated limited clonal clustering of the 36 isolates (Fig. 1) .
Sixteen isolates were selected for in vitro synergy testing, including all PDR A. baumannii isolates and 12 other isolates from different clonal subgroups. In vitro synergy by time-kill was detected with polymyxin B-rifampin (n ϭ 9; 56%), polymyxin B-tigecycline (n ϭ 7; 44%), and tigecycline-rifampin combinations (n ϭ 3; 19%) by time-kill methods. Checkerboard methods reported in vitro synergy with polymyxin Brifampin (n ϭ 3; 19%), rifampin-tigecycline (n ϭ 3; 19%), and polymyxin B-tigecycline combinations (n ϭ 2; 12%). Etest methods demonstrated in vitro synergy only to the polymyxin B-rifampin combination (n ϭ 1; 6% 
